An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer-Reference-Cited by-同舟云学术

An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer

Published:2005 Issue:2-3 Volume:68 Page:171-178
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Ueno Hideki,Okusaka Takuji,Ikeda Masafumi,Takezako Yoriko,Morizane Chigusa

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference29 articles.

1. Evans DB, Abbruzzese JL, Willett CG: Cancer of the pancreas; in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott, 2001, pp 1126-1161.

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Phase II trial of gemcitabine (2,2?-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

4. Phase II study of gemcitabine in patients with advanced pancreatic cancer

5. Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial;Oncology Letters;2024-02-19

2. Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project;Molecular and Clinical Oncology;2023-10-25

3. Polymeric micelles assisted combinatorial therapy: Is it new hope for pancreatic cancer?;European Polymer Journal;2023-02

4. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial;European Journal of Cancer;2022-10

5. A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma;Medical Science Monitor;2022-06-03